Sepsis Diagnostics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Sepsis Diagnostics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The sepsis diagnostics market was valued at USD 596.61 million in 2021, registering a CAGR of 7.74% during the forecast period.

Increasing incidences of sepsis in COVID-19 patients is anticipated to have a positive impact on the market studied. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, “2020 National and State Healthcare-Associated Infections Progress Report”, the analysis of the 2020 acute care hospitals standardized infection ratios found significant increases in central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated events, and methicillin-resistant Staphylococcus aureus bacteremia compared to 2019. The largest increases occurred during quarter 4 of 2020. ​Furthermore, according to a study published by PLOS in August 2021, “Immunometabolic signatures predict the risk of progression to sepsis in COVID-19,” COVID-19 patients are at the highest risk of developing sepsis. Hence, this is expected to create new opportunities for novel diagnosis in the market studied.​

The major factors for the growth of the sepsis diagnostics market include the increasing burden of sepsis, the growing burden of hospital-acquired infections, the increasing number of pneumonia cases, the rise in the number of sepsis procedures, and an increase in funding for sepsis-related research activities. Hospital-acquired infections (HAIs) are the most common complications among hospitalized patients. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, “2020 National and State Healthcare-Associated Infections Progress Report”, about 24%, 35%, and 15% increase in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia between 2019 and 2020 in United States.​ The rising bloodstream infections will lead to increased adoption of sepsis diagnostic products. Additionally, in June 2021, the collaboration led by the University of Liverpool has received more than GBP 3 million in funding for a new intervention that will actively prevent, treat and evaluate maternal sepsis.

Thus, the rise in the prevalence of sepsis and increase in funding for research activities for sepsis diagnosis are expected to drive the overall growth of the sepsis diagnosis market over the forecast period.

Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern healthcare. Moreover, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment. These requirements make molecular diagnostics (MDx) an attractive approach to consider for sepsis diagnostics.

Molecular diagnostics have attracted several multinational companies and institutions, owing to their easy feasibility and accuracy in detection methods. The blood culture analysis for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method. However, the cost of molecular diagnostics has remained very high, as compared to conventional procedures, which restricts its market growth. Several companies are investing in point-of-care molecular diagnostics for the early diagnosis of bacterial and viral pathogens and better patient management. For instance, in October 2020, Immunexpress launched a rapid SeptiCyte, a one-hour molecular diagnostic test for sepsis in Europe on Biocartis’ Idylla platform. This is one of the first rapid, fully-integrated, and immune response-based tests to aid clinicians with a sepsis diagnosis.​

Furthermore, researchers are attempting to develop a molecular diagnostic that can detect the COVID-19 and sepsis, as well as discriminate between the two. In November 2020, the Hellenic Institute for the Study of Sepsis and, in part by Sanmina Corporation, funded a study and developed a novel optical biosensor for the early diagnosis of sepsis and severe COVID-19. These developments are expected to have a positive impact on the growth of this segment.

North America is found to hold a major share of the sepsis diagnostics market and is expected to show a similar trend over the forecast period, without significant fluctuations. According to the Centers for Disease Control and Prevention, in August 2021, approximately 1.7 million adults in America develop sepsis, and nearly 270,000 Americans die due to sepsis. It was also found that 1 in 3 patients who die in a hospital has sepsis. Thus, the high incidence rate of the disease in the country will boost its diagnosis, thus, boosting the market.​

Moreover, rising investments in the fields of research and development for the diagnosis of sepsis will also boost the market. For instance, in April 2020, Cytovale Inc. expanded its partnership with the Biomedical Advanced Research and Development Authority (BARDA) for diagnosing sepsis in patients with potential respiratory infections, including COVID-19. The research is estimated to stand at the cost of USD 5.9 million, with approximately USD 3.83 contributed by the Biomedical Advanced Research and Development Authority (BARDA), thus, driving the market.​

Therefore, the rising prevalence of sepsis and increasing investments in the research and development of sepsis diagnosis may augment the growth of the market in United States.

The sepsis diagnostics market is moderately consolidated owing to the presence of a few key players. The market is expected to drive due to the products launched by the key players in the market and the rise in research initiatives on sepsis diagnostics by the key players. Some of the market players are Abbott, Becton, Dickinson, and Company, bioMérieux SA, BrUnited Kingdomer Corporation, F. Hoffmann-LA Roche Ltd, and Immunexpress Inc., among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support